Myocardial T1 mapping: where are we now and where are we going?

References

• Kramer CM, Barkhausen J, Flamm SD, Kim RJ, Nagel E; Society for Cardiovascular Magnetic Resonance Board of Trustees Task Force on Standardized Protocols. Standardized cardiovascular magnetic resonance imaging (CMR) protocols, society for cardiovascular magnetic resonance: board of trustees task force on standardized protocols. J Cardiovasc Magn Reson. 2008;10:35.
   Web of Science ®Google Scholar
• Greenwood JP, Maredia N, Younger JF, et al. Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial. Lancet. 2012;379:453–460.
   PubMed Web of Science ®Google Scholar
• Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977–1985.
   PubMed Web of Science ®Google Scholar
• Jiji RS, Kramer CM. Cardiovascular magnetic resonance: applications in daily practice. Cardiol Rev. 2011;19:246–254.
   Web of Science ®Google Scholar
• Vignaux O. Cardiac sarcoidosis: spectrum of MRI features. AJR Am J Roentgenol. 2005;184:249–254.
   PubMed Web of Science ®Google Scholar
• Moon JC, McKenna WJ, McCrohon JA, Elliott PM, Smith GC, Pennell DJ. Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance. J Am Coll Cardiol. 2003;41:1561–1567.
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Neubauer S. The prognostic value of late gadolinium enhancement CMR in nonischemic cardiomyopathies. Curr Cardiol Rep. 2013;15:326.
   Web of Science ®Google Scholar
• Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5:370–377.
   PubMed Web of Science ®Google Scholar
• Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51:2414–2421.
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler K, Meier CG, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206–1216.
   PubMed Web of Science ®Google Scholar
• Moon JC, Messroghli DR, Kellman P, et al; Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92.
   PubMed Web of Science ®Google Scholar
• Piechnik SK, Ferreira VM, Lewandowski AJ, et al. Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLI. J Cardiovasc Magn Reson. 2013;15:13.
   Web of Science ®Google Scholar
• Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141–146.
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007;26:1081–1086.
   PubMed Web of Science ®Google Scholar
• Piechnik SK, Ferreira VM, Dall’Armellina E, et al. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69.
   PubMed Web of Science ®Google Scholar
• Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB. Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn Reson Med. 2014;71:2082–2095.
   PubMed Web of Science ®Google Scholar
• Kellman P, Hansen MS. T1-mapping in the heart: accuracy and precision. J Cardiovasc Magn Reson. 2014;16:2.
   PubMed Web of Science ®Google Scholar
• Higgins DM, Moon JC. Review of T1 mapping methods: comparative effectiveness including reproducibility issues. Curr Cardiovasc Imaging Rep. 2014;7:9252.
   Google Scholar
• Rogers T, Dabir D, Mahmoud I, et al. Standardization of T1 measurements with MOLLI in differentiation between health and disease – the ConSept study. J Cardiovasc Magn Reson. 2013;15:78.
   PubMed Web of Science ®Google Scholar
• Messroghli DR, Plein S, Higgins DM, et al. Human myocardium: single-breath-hold MR T1 mapping with high spatial resolution – reproducibility study. Radiology. 2006;238:1004–1012.
   Web of Science ®Google Scholar
• Roujol S, Weingärtner S, Foppa M, et al. Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology. Epub April 4, 2014.
   Google Scholar
• Bull S, White SK, Piechnik SK, et al. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99:932–937.
   PubMed Web of Science ®Google Scholar
• Ferreira VM, Piechnik SK, Dall’Armellina E, et al. Non-contrast T1-mapping detects acute myocardial edema with high diagnostic accuracy: a comparison to T2-weighted cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:42.
   PubMed Web of Science ®Google Scholar
• Karamitsos TD, Piechnik SK, Banypersad SM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2013;6:488–497.
   PubMed Web of Science ®Google Scholar
• Sado DM, White SK, Piechnik SK, et al. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging. 2013;6:392–398.
   PubMed Web of Science ®Google Scholar
• Sado D, White SK, Piechnik SK, et al. Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease. J Cardiovasc Magn Reson. 2013;15(Suppl 1):O71.
   Google Scholar
• Pedersen SF, Thrysøe SA, Robich MP, et al. Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused acute myocardial infarction. J Cardiovasc Magn Reson. 2012;14:59.
   PubMed Web of Science ®Google Scholar
• Banypersad SM, Fontana M, Maestrini V, et al. Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis – a 2 year follow-up study. J Cardiovasc Magn Reson. 2014;16(1):O5.
   Google Scholar
• Jellis CL, Kwon DH. Myocardial T1 mapping: modalities and clinical applications. Cardiovasc Diagn Ther. 2014;4:126–137.
   PubMedGoogle Scholar
• Raman FS, Kawel-Boehm N, Gai N, et al. Modified look-locker inversion recovery T1 mapping indices: assessment of accuracy and reproducibility between magnetic resonance scanners. J Cardiovasc Magn Reson. 2013;15:64.
   PubMed Web of Science ®Google Scholar
• Brown L. Cardiac extracellular matrix: a dynamic entity. Am J Physiol Heart Circ Physiol. 2005;289:H973–H974.
   Web of Science ®Google Scholar
• Mewton N, Liu CY, Croisille P, Bluemke D, Lima JA. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J Am Coll Cardiol. 2011;57:891–903.
   PubMed Web of Science ®Google Scholar
• Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574–1580.
   PubMed Web of Science ®Google Scholar
• Flett AS, Sado DM, Quarta G, et al. Diffuse myocardial fibrosis in severe aortic stenosis: an equilibrium contrast cardiovascular magnetic resonance study. Eur Heart J Cardiovasc Imaging. 2012;13:819–826.
   PubMed Web of Science ®Google Scholar
• Maceira AM, Joshi J, Prasad SK, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2005;111:186–193.
   PubMed Web of Science ®Google Scholar
• Cheng AS, Banning AP, Mitchell AR, Neubauer S, Selvanayagam JB. Cardiac changes in systemic amyloidosis: visualisation by magnetic resonance imaging. Int J Cardiol. 2006;113:E21–E23.
   Google Scholar
• Banypersad SM, Sado DM, Flett AS, et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: an equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013;6:34–39.
   PubMed Web of Science ®Google Scholar
• Fontana M, Banypersad SM, Treibel TA, et al. Native T1 mapping in transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7:157–165.
   PubMed Web of Science ®Google Scholar
• O’Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52:326–335.
   Web of Science ®Google Scholar
• Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012;10:411–422.
   PubMed Web of Science ®Google Scholar
• Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2008;10:42.
   PubMed Web of Science ®Google Scholar
• Friedrich MG, Marcotte F. Cardiac magnetic resonance assessment of myocarditis. Circ Cardiovasc Imaging. 2013;6:833–839.
   PubMed Web of Science ®Google Scholar
• Park CH, Choi EY, Greiser A, Paek MY, Hwang SH, Kim TH. Diagnosis of acute global myocarditis using cardiac MRI with quantitative t1 and t2 mapping: case report and literature review. Korean J Radiol. 2013;14:727–732.
   Web of Science ®Google Scholar
• Verhaert D, Thavendiranathan P, Giri S, et al. Direct T2 quantification of myocardial edema in acute ischemic injury. JACC Cardiovasc Imaging. 2011;4:269–278.
   PubMed Web of Science ®Google Scholar
• Ferreira VM, Piechnik SK, Dall’Armellina E, et al. T(1) mapping for the diagnosis of acute myocarditis using CMR: comparison to T2-weighted and late gadolinium enhanced imaging. JACC Cardiovasc Imaging. 2013;6:1048–1058.
   PubMed Web of Science ®Google Scholar
• Ferreira VM, Piechnik SK, Dall’Armellina E, et al. Native T1-mapping detects the location, extent and patterns of acute myocarditis without the need for gadolinium contrast agents. J Cardiovasc Magn Reson. 2014;16:36.
   PubMed Web of Science ®Google Scholar
• Puntmann VO, D’Cruz D, Smith Z, et al. Native myocardial T1 mapping by cardiovascular magnetic resonance imaging in subclinical cardiomyopathy in patients with systemic lupus erythematosus. Circ Cardiovasc Imaging. 2013;6:295–301.
   PubMed Web of Science ®Google Scholar
• Bonow RO, Carabello BA, Chatterjee K, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2008;52:e1–e142.
   Web of Science ®Google Scholar
• Taylor J. ESC/EACTS Guidelines on the management of valvular heart disease. Eur Heart J. 2012;33:2371–2372.
   Web of Science ®Google Scholar
• Vahanian A, Baumgartner H, Bax J, et al; Task Force on the Management of Valvular Hearth Disease of the European Society of Cardiology; ESC Committee for Practice Guidelines. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007;28:230–268.
   PubMed Web of Science ®Google Scholar
• Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol. 2012;60:1854–1863.
   PubMed Web of Science ®Google Scholar
• Milano AD, Faggian G, Dodonov M, et al. Prognostic value of myocardial fibrosis in patients with severe aortic valve stenosis. J Thorac Cardiovasc Surg. 2012;144:830–837.
   PubMed Web of Science ®Google Scholar
• Shin S, Park PW, Han WS, Sung KI, Kim WS, Lee YT. Mass reduction and functional improvement of the left ventricle after aortic valve replacement for degenerative aortic stenosis. Korean J Thorac Cardiovasc Surg. 2011;44:399–405.
   Google Scholar
• Weidemann F, Herrmann S, Stork S, et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation. 2009;120:577–584.
   PubMed Web of Science ®Google Scholar
• Singh A, Ford I, Greenwood JP, et al. Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations. BMJ Open. 2013;3:e004348.
   Web of Science ®Google Scholar
• Ellims AH, Shaw JA, Stub D, et al. Diffuse myocardial fibrosis evaluated by post-contrast t1 mapping correlates with left ventricular stiffness. J Am Coll Cardiol. 2014;63:1112–1118.
   PubMedGoogle Scholar
• Mascherbauer J, Marzluf BA, Tufaro C, et al. Cardiac magnetic resonance postcontrast T1 time is associated with outcome in patients with heart failure and preserved ejection fraction. Circ Cardiovasc Imaging. 2013;6:1056–1065.
   PubMed Web of Science ®Google Scholar
• Wong TC, Piehler KM, Kang IA, et al. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35:657–664.
   PubMed Web of Science ®Google Scholar
• Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6:587–596.
   PubMed Web of Science ®Google Scholar
• Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260–2264.
   PubMed Web of Science ®Google Scholar
• Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156–2164.
   PubMed Web of Science ®Google Scholar
• Puntmann VO, Voigt T, Chen Z, et al. Native T1 mapping in differentiation of normal myocardium from diffuse disease in hypertrophic and dilated cardiomyopathy. JACC Cardiovasc Imaging. 2013;6:475–484.
   PubMed Web of Science ®Google Scholar
• Florian A, Ludwig A, Rosch S, Yildiz H, Sechtem U, Yilmaz A. Myocardial fibrosis imaging based on T1-mapping and extracellular volume fraction (ECV) measurement in muscular dystrophy patients: diagnostic value compared with conventional late gadolinium enhancement (LGE) imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1004–1012.
   PubMed Web of Science ®Google Scholar
• Vermes E, Pucheux J, Delhommais A, Alison D, Brunereau L. Cardiac magnetic resonance T1 mapping pre and post contrast in heart transplant patients with clinical antibody-mediated rejection: a preliminary experience. J Cardiovasc Magn Reson. 2014;16(Suppl 1):P100.
   Google Scholar
• Edwards NC, Moody WE, Chue CD, Ferro CJ, Townend JN, Steeds RP. Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance. JACC Cardiovasc Imaging. 2014;7:703–714.
   PubMed Web of Science ®Google Scholar
• Frustaci A, Chimenti C, Bellocci F, Morgante E, Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation. 1997;96:1180–1184.
   PubMed Web of Science ®Google Scholar
• Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol. 2008;51:802–809.
   PubMed Web of Science ®Google Scholar
• Beinart R, Khurram IM, Liu S, et al. Cardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm. 2013;10:1325–1331.
   PubMed Web of Science ®Google Scholar
• Ling LH, McLellan AJ, Taylor AJ, et al. Magnetic resonance post-contrast T1 mapping in the human atrium: validation and impact on clinical outcome following catheter ablation for atrial fibrillation. Heart Rhythm. 2014;11:1551–1559.
   PubMed Web of Science ®Google Scholar
• Ling LH, Kistler PM, Ellims AH, et al. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol. 2012;60:2402–2408.
   PubMed Web of Science ®Google Scholar
• Ling LH, Kalman JM, Ellims AH, et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol. 2013;6:697–704.
   Web of Science ®Google Scholar